Zacks upgrades CONMED shares — 5 quick facts

Zacks analysts upgraded CONMED shares from a “hold” rating to a “buy” rating, according to EMQ News & Analysis.

Advertisement

Here are five quick facts:

 

1. Zacks has a $45 price objective on CONMED stock.

 

2. On Jan. 14, CONMED shares fell 2.4 percent.

 

3. The company has a 50-day moving average of $42.10.

 

4. The 200-day moving average is $48.62.

 

5. CONMED has a market cap of $1.08 billion.

 

More articles on devices:
SeaSpine, K2M, Smith & Nephew & more: 19 key notes
DeGen Medical launches Hyper-C Anterior Cervical Plate System: 4 key notes
Medical Compression Systems seeks buyer: 3 things to know

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.